Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Citi
Novartis
Dow
Healthtrust
Colorcon
US Department of Justice
Deloitte
Federal Trade Commission
Express Scripts

Generated: February 18, 2018

DrugPatentWatch Database Preview

FIRAZYR Drug Profile

« Back to Dashboard

When do Firazyr patents expire, and what generic alternatives are available?

Firazyr is a drug marketed by Shire Orphan Therap and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fourteen patent family members in thirty-three countries.

The generic ingredient in FIRAZYR is icatibant acetate. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the icatibant acetate profile page.
Summary for FIRAZYR
International Patents:114
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 20
Clinical Trials: 7
Patent Applications: 1
Drug Prices:see details
DailyMed Link:FIRAZYR at DailyMed
Drug patent expirations by year for FIRAZYR
Pharmacology for FIRAZYR

US Patents and Regulatory Information for FIRAZYR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Orphan Therap FIRAZYR icatibant acetate INJECTABLE;SUBCUTANEOUS 022150-001 Aug 25, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Shire Orphan Therap FIRAZYR icatibant acetate INJECTABLE;SUBCUTANEOUS 022150-001 Aug 25, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for FIRAZYR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 10 mg/mL ➤ Subscribe 8/25/2015

International Patents for FIRAZYR

Supplementary Protection Certificates for FIRAZYR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
499 Luxembourg ➤ Try a Free Trial 91499, EXPIRES: 20141121
00359 Netherlands ➤ Try a Free Trial PRODUCT NAME: ICATIBANT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, BIJ VOORKEUR ICATIBANTACETAAT; REGISTRATION NO/DATE: EU/1/048/461/001 20080711
/2008 Austria ➤ Try a Free Trial PRODUCT NAME: ICATIBANT, WAHLWEISE IN FORM EINES PHYSIOLOGISCH ANNEHMBAREN SALZES, EINSCHLIESSLICH ICATIBANT-ACETAT; REGISTRATION NO/DATE: EU/1/08/461/001 20080711
0359 Netherlands ➤ Try a Free Trial 300359, 20091121, EXPIRES: 20141120
C0002 France ➤ Try a Free Trial PRODUCT NAME: ICATIBANT, EVENTUELLEMENT SOUS FORME DE SEL PHYSIOLOGIQUEMENT ACCEPTABLE, NOTAMMENT L?ACETATE D?ICATIBANT; REGISTRATION NO/DATE IN FRANCE: EU/1/08/461/001 DU 20080711; REGISTRATION NO/DATE AT EEC: EU/1/08/461/001 DU 20080711
C/GB09/002 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ICATIBANT, OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF, INCLUDING ICATIBANT ACETATE; REGISTERED: UK EU/1/08/461/001 20080711
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Federal Trade Commission
Julphar
AstraZeneca
Cipla
Medtronic
Baxter
UBS
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot